WHO warns pandemic still a public health emergency, urges greater surveillance including testing and sequencing

WHO panel says no evidence yet that new omicron subvariants are more dangerous than others that are circulating

Posted on

The omicron sublineages named BQ.1 and XBB do not appear to have immune escape mutations that warrant being designated as variants of concern, a World Health Organization advisory panel said Friday.

The decision will be reassessed regularly to ensure there is no change that might warrant a new designation, said the statement.

As of Oct. 25, the XBB and XBB.1 lineages had been detected in 35 countries, according to a WHO weekly update from Thursday. The two are BA.2.10.1 and BA.2.75 recombinants, which were found in 26 countries in the previous week.

“There has been a broad increase in prevalence of XBB in regional genomic surveillance, but it has not yet been consistently associated with an increase in new infections,” the panel wrote. However, early evidence does suggest a higher reinfection risk compared with other circulating omicron variants.

BQ.1 is a sublineage of BA.5, which remains dominant globally, accounting for 77.1% of sequences forwarded to a centralized database in the week through Oct. 23. BQ.1 has been found in 65 countries.

“While there are no data on severity or immune escape from studies in humans, BQ.1* is showing a significant growth advantage over other circulating Omicron sublineages in many settings, including Europe and the US, and therefore warrants close monitoring,” said the panel.

The real risk of the variants depends on the level of immunity in a given region, it added. And with waning immune response from initial waves of omicron infection, and further evolution of omicron variants, “it is likely that reinfections may rise further,” said the statement.

In the U.S., known cases of COVID are continuing to ease and now stand at their lowest level since mid-April, although the true tally is likely higher given how many people overall are testing at home, where the data are not being collected.

The daily average for new cases stood at 37,412 on Thursday, according to a New York Times tracker, down 3% from two weeks ago. The daily average for hospitalizations was up 1% at 27,002, while the daily average for deaths is down 5% to 358. 

Coronavirus Update: MarketWatch’s daily roundup has been curating and reporting all the latest developments every weekday since the coronavirus pandemic began

Other COVID-19 news you should know about:

• Gilead Sciences Inc.
GILD,
+11.12%

said sales of its COVID treatment Veklury, formerly known as remdesivir, fell 52% to $925 million in the third quarter, driven by lower rates of COVID-19-related hospitalizations compared to the third quarter of 2021.” Last month, Gilead said the World Health Organization expanded its guidance to recommend remdesivir for treatment of patients with severe symptoms.

• The pandemic devastated poor children’s well-being, not just by closing their schools, but also by taking away their parents’ jobs, sickening their families and teachers, and adding chaos and fear to their daily lives, the Associated Press reported, citing an analysis of test scores that was shared on an exclusive basis. The analysis found the average student lost more than half a school year of learning in math and nearly a quarter of a school year in reading—with some district averages slipping by more than double those amounts, or worse. Online learning played a major role, but students lost significant ground even where they returned quickly to schoolhouses, especially in math scores in low-income communities.

• Optimism among U.S. companies in China has hit record low levels, an annual survey showed on Friday, as competitive, economic, and regulatory challenges compound the stresses already imposed by Beijing’s ongoing zero-COVID policies, Reuters reported. Just 55% of 307 companies surveyed by the American Chamber of Commerce in Shanghai and consulting firm PwC China described themselves as optimistic about the five-year business outlook. The reading is the lowest in the survey’s 23-year history and worse than in 2020, when COVID first surfaced, and during the trade standoff between Beijing and Washington in 2019.

• The Chinese city of Shanghai has ordered mass testing on all 1.3 million residents of its downtown Yangpu district and is confining them to their homes at least until results are known, the AP reported. The demand is an echo of measures ordered over the summer that led to a two-month lockdown of the entire city of 25 million that devastated the local economy, prompting food shortages and rare confrontations between residents and the authorities.

Here’s what the numbers say:

The global tally of confirmed cases of COVID-19 topped 629.6 million on Friday, while the death toll rose above 6.58 million, according to data aggregated by Johns Hopkins University.

The U.S. leads the world with 97.4 million cases and 1,070,064fatalities.

The Centers for Disease Control and Prevention’s tracker shows that 226.9 million people living in the U.S., equal to 68.4% of the total population, are fully vaccinated, meaning they have had their primary shots.

So far, just 22.8 million Americans have had the updated COVID booster that targets the original virus and the omicron variants, equal to 7.3% of the overall population.

Leave a Reply

Your email address will not be published. Required fields are marked *